Erschienen in:
19.04.2017 | Original Paper
Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to punctate inner choroidopathy
verfasst von:
T. Barth, F. Zeman, H. Helbig, M.-A. Gamulescu
Erschienen in:
International Ophthalmology
|
Ausgabe 3/2018
Einloggen, um Zugang zu erhalten
Abstract
Purpose
To assess the outcome of patients with choroidal neovascularization (CNV) secondary to punctate inner choroidopathy (PIC) receiving intravitreal anti-VEGF (vascular endothelial growth factor) injections.
Methods
Sixteen eyes of 16 patients diagnosed with CNV secondary to PIC were retrospectively assessed.
Results
Eleven women and five men with a mean age of 35 years (SD 11, range 16–56 years) received intravitreal anti-VEGF for PIC-related CNV. On average, 3.5 injections (SD 2.7, range 1–9) were given per eye. Thirteen eyes were treated with bevacizumab, two eyes with ranibizumab and one eye received both substances. The mean follow-up was 15 months (SD 11, range 6–40 months). BCVA improved in eight eyes (mean Δ +2.8 lines), remained stable in four eyes and decreased in four eyes (mean Δ −4.3 lines).
Conclusions
CNV development is a frequent complication of PIC. Intravitreal anti-VEGF therapy seems to be safe and effective for PIC-related CNV.